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Effective therapies for stroke are still limited due to its complex pathological manifestations.
QiShenYiQi (QSYQ), a component-based Chinese medicine capable of reducing organ
injury caused by ischemia/reperfusion, may offer an alternative option for stroke treatment
and post-stroke recovery. Recently, we reported a beneﬁcial effect of QSYQ for acute
stroke via modulation of the neuroinﬂammatory response. However, if QSYQ plays a role in
subacute stroke remains unknown. The pharmacological action of QSYQ was investigated
in experimental stroke rats which underwent 90 min ischemia and 8 days reperfusion in this
study. Neurological and locomotive deﬁcits, cerebral infarction, brain edema, and BBB
integrity were assessed. TMT-based quantitative proteomics were performed to identify
differentially expressed proteins following QSYQ treatment. Immunohistochemistry,
western blot analysis, RT-qPCR, and ELISA were used to validate the proteomics data
and to reveal the action mechanisms. Therapeutically, treatment with QSYQ (600 mg/kg)
for 7 days signiﬁcantly improved neurological recovery, attenuated infarct volume and brain
edema, and alleviated BBB breakdown in the stroke rats. Bioinformatics analysis indicated
that protein galectin-3 and its mediated inﬂammatory response was closely related to the
beneﬁcial effect of QSYQ. Specially, QSYQ (600 mg/kg) markedly downregulated the
mRNA and protein expression levels of galectin-3, TNF-α, and IL-6 in CI/RI brain as well as
serum levels of TNF-α and IL-6. Overall, our ﬁndings showed that the effective action of
QSYQ against the subacute phase of CI/RI occurs partly via regulating galectin-3 mediated
inﬂammatory reaction.
Keywords: qishenyiqi, cerebral ischemia/reperfusion injury, TMT-based quantitative proteomics analysis,
inﬂammatory response, galectin-3
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INTRODUCTION

At present, it is believed that immune-inﬂammatory response
is an important endogenous mechanism involved in the
pathophysiological process of CI/RI (Famakin, 2014). An antiinﬂammatory strategy appears to be a favorite therapeutic target,
given its pleiotropic roles in the acute damage to long term
recovery phase of ischemic stroke (Peng et al., 2019). Galectin-3 is
a unique chimera-type member of the galectin family and exerts
various functions depending on cell type and cellular location
(Yip et al., 2017). Recent studies suggested that galectin-3 may
serve as a promising prognostic biomarker as well as a potential
therapeutic target for cardiovascular and cerebrovascular diseases
(Shen et al., 2016; Dong et al., 2018). Accumulated evidence has
indicated that galectin-3 appeared to function as a signiﬁcant
regulator participating in the neuroinﬂammatory reaction caused
by cerebral ischemia and reperfusion (Shin, 2013; Rahimian et al.,
2018). Interestingly, Burguillos et al. reported that microgliasecreted galectin-3 acted as an endogenous ligand for Toll-like
receptor 4 (TLR-4) activation and deteriorated typical TLR4dependent inﬂammatory response after cerebral ischemia
(Burguillos et al., 2015).
In the present study, we aimed to explore the
pharmacodynamic effect of QSYQ against the cerebral injury
induced by ischemic stroke in the subacute phase. Subsequently,
tandem mass tag (TMT)-based quantitative proteomics analysis
followed by experimental veriﬁcation was executed to explain the
galectin-3 mediated neuroinﬂammatory mechanism of QSYQ
treatment in response to CI/RI of the subacute phase.

Stroke is recognized as one of the main leading causes of death
and serious long-term disability, as well as cognitive functional
impairment, worldwide (Benjamin et al., 2019). Of all strokes,
ischemic stroke incidents account for approximately 87%
(Benjamin et al., 2019). Although intensive basic and clinical
research has uncovered multiple modiﬁable risk factors (such as
high systolic blood pressure, high fasting plasma glucose, and
high total cholesterol) (Feigin et al., 2016), and has revealed many
potential molecular mechanisms (such as inﬂammatory response
(Jin et al., 2013), oxidative stress (Li et al., 2018), blood-brain
barrier dysfunction (Jiang et al., 2018), activation of apoptotic and
autophagic pathways (Kalogeris et al., 2012), mitochondrial
dysfunction (Yang et al., 2018), and complement activation of
stroke (Ma et al., 2019), effective therapies are still limited.
Currently, the standard clinical therapy for appropriate
patients with acute ischemic stroke are tissue plasminogen
activator (tPA)-mediated intravenous thrombolysis and
executing intra-arterial thrombectomy to realize recanalization
(Dong et al., 2017; Goda et al., 2020). However, the major
problems of the relatively narrow therapeutic time window
and a high risk of hemorrhagic transformation in tPA
treatment should not be ignored (Dong et al., 2017; Puig
et al., 2017). Reperfusion injury following the restoration of
blood supply may also result in more adverse stroke outcomes
via complicated pathological processes (Lin et al., 2016). It is
believed that cerebral ischemia/reperfusion injury (CI/RI) has
become an increasingly critical challenge for post-stroke recovery
(Pan et al., 2007). Thus, it is crucial to discover novel and
alternative therapies for ischemic stroke.
In China, herbal remedies have been historically applied in
the treatment of stroke and stroke-associated symptoms based
on the theory of traditional Chinese medicine (TCM) (Sun et al.,
2015; Han et al., 2017a). Qishen Yiqi (QSYQ) formula, which is
composed of Astragalus membranaceus (Fisch.) Bge.
(Huangqi), Salvia miltiorrhiza Bge. (Danshen), Panax
notoginseng (Burk.) F. H. Chen (Sanqi), and Dalbergia
odorifera T. Chen (Jiangxiang), is a typical component-based
Chinese medicine that was approved by the State Food and
Drug Administration of China in 2003 for treatment of angina
pectoris of coronary heart disease origin with Qi deﬁciency and
blood stasis syndrome (Cao et al., 2017), and secondary
prevention of myocardial infarction (Shang et al., 2013).
Recently, the major active ingredients in QSYQ, such as
astragaloside IV, calycosin, calycosin-7-O-β-D-glycoside,
formononetin, salvianolic acid A, salvianolic acid B,
tanshinone IIA, notoginsenoside R1, ginsenoside Rg1, and
ginsenoside Rb1(Yu et al., 2017; Zhang et al., 2018), have
been reported to have therapeutic potential in acute and
subacute phases of ischemic stroke via various functional
mechanisms, especially immune-inﬂammatory response
related mechanism (Han et al., 2017b; Zhang et al., 2020).
Furthermore, we have found the protective action of QSYQ
against acute ischemic stroke via regulating neuroinﬂammatory
network mobilization in a mouse model of cerebral ischemia
and reperfusion (Wang et al., 2020).
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MATERIALS AND METHODS
Drugs and Reagents
QSYQ (drug approval number: Z20030139; batch number:
20160604), which was supplied by Tasly Pharmaceutical
Group Co., Ltd. (Tianjin, China), was prepared according to
the ratio of Huangqi: Danshen: Sanqi: Jiangxiang oil  148.01:
70.35:70.35:11.97 and dissolved in ultrapure water to make a
solution at concentrations of 15 mg/ml, 30 mg/ml, and 60 mg/ml
for experiments. Nimodipine (Nim) (drug approval number:
H14022821) was purchased from Yabao Pharmaceutical Group
Co., Ltd. (Taiyuan, China). Chromatographic-grade methanol
and acetonitrile were purchased from Merck (Darmstadt,
Germany). Water was puriﬁed using the Millipore-Q water
puriﬁcation system (Millipore, Milford, MA, United States).
Standards
of
tanshinol,
calycosin-7-O-β-D-glycoside,
protocatechualdehyde, formononetin, and rosmarinic acid
were purchased from the National Institutes for Food and
Drug Control of China (Beijing, China). Standards of
lithospermic acid, ononin, and calycosin were purchased from
Tianjin Shilan Technology Co., Ltd. (Tianjin, China). Standards
of salvianolic acid A, salvianolic acid B, salvianolic acid D,
salvianolic acid T, and salvianolic acid U were obtained from
Tianjin Tasly Pharmaceutical Group Co., Ltd. (Tianjin, China).
The purities of the above standards were more than 98%. 2, 3, 5Triphenyl-2H-Tetrazolium Chloride (TTC) solution (2%,
G3005), paraformaldehyde (4%, P1110), RIPA lysis buffer
(R0020), PMSF (100mM, P0100), BCA Protein Assay Kit
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Technology Co., Ltd.) and clean water were provided ad
libitum. Before the surgery, animals were fasted for 12 h, but
with free access to water. The behavioral assessment was executed
during the rats’ active periods.

(PC0020–50T), and SDS-PAGE Gel Kit (P1200–50T) were
purchased from Solarbio (Beijing, China). Evans Blue was
purchased from Meilunbio (MB4680-5°g, Dalian, China).
Isoﬂurane (Lot No. B506) was purchased from Ruiwode
Lifescience Co., Ltd. (Shenzhen, China). Omnipaque (300 mg
I/ml, drug approval number: H20000,595) was purchased from
GE Pharmaceutical Co., Ltd. (Shanghai, China). Tandem mass
tag (TMT) (6-plex) isobaric label reagents were purchased from
Thermo Fisher Scientiﬁc (Waltham, MA, United States). Sodium
dodecyl sulfate (SDS), DL-dithiothreitol (DTT), Iodoaceamide
(IAA), Triethylamine borane (TEAB), and urea were obtained
from Bio-Rad (Hercules, CA, United,States). Trypsin was
obtained from Promega (Madison, WI). Tris was obtained
from Sigma (St. Louis, MO, United States). Anti-Galectin-3
antibody was purchased from the Abcam Company (ab53082,
Cambridge, United Kingdom). Anti-β-actin antibody was
purchased from Cell Signaling Technology (8457S, Beverly,
MA, United States). Goat anti-rabbit IgG H&L was purchased
from Zhongshan Jingqiao Biotechnology, Inc. (ZB-5301, Beijing,
China). Cytokine IL-6 and TNF-α ELLISA kits were obtained
from Shanghai Zhuocai Biotechnology Co., Ltd. (Shanghai,
China).

Middle Cerebral Artery Occlusion Model
and Drug Treatment
Before the surgery, rats were anesthetized with 4% isoﬂurane in
70% nitrous oxide (N2O)/30% oxygen (O2). Then, isoﬂurane was
lowered to 2.5% to maintain anesthesia using a small animal
anesthesia machine (Matrix VIP 3,000; Midmark, United States).
Throughout all surgical procedures, the animal was placed on a
heating pad to keep body temperature at 37°C. Surgery was
performed using transient MCAO technique as described
elsewhere with proper modiﬁcation (Uluc et al., 2011; Gubskiy
et al., 2018; Lopez and Vemuganti, 2018). A ventral midline
incision (∼1 cm) was made at the sterile neck and the left
common carotid artery (CCA), external cerebral artery (ECA),
and internal cerebral artery (ICA) were orderly exposed. After
temporarily blocking the left CCA and ICA using two
microsurgical clips, two sterile 4–0 silk sutures were placed
around the left ECA: one tight ligature was tied as distally as
possible from the bifurcation and the other loose ligature was put
near the bifurcation. Then, a small hole was created between two
silk sutures on the left ECA with a microsurgical scissor and a
3.0–5.0 cm length of silicone-coated 4-0 nylon monoﬁlament
(diameter with coating 0.32 ± 0.02 mm, Guangzhou Jialing
Biotechnology Co., Ltd., Guangzhou, China) was inserted into
the left ECA and gently guided toward the ICA. The
microsurgical clip from the ICA was removed and advanced
toward the monoﬁlament until the tip occluded the origin of the
left middle cerebral artery (MCA), resulting in a decline of local
cerebral blood ﬂow to 20% of baseline. After 90 min MCAO, the
perfusion of blood ﬂow was regained by withdrawing the
monoﬁlament. Before its closing, the wound area was
moisturized with sterile saline and lidocaine was applied as a
topical analgesic. Isotonic saline was intraperitoneally injected to
prevent dehydration. After wound closure, bupivacaine was
applied along the sutures and the animal was placed in a
temperature-controlled recovery chamber to monitor its
behavior for 1–2 h. Finally, the rat was put back to the
housing cage and moistened rodent chow was placed on the
bottom of the cage to facilitate eating. Sham-operated rats were
handled in the same way like the model group, although the
monoﬁlament was not used to achieve the occlusion of MCA.

High Performance Liquid Chromatography
Analysis
Mixed standards were prepared as follows: all standards were
weighed accurately and dissolved in 10 ml of methanol. Mixed
standards were then ﬁltered using a 0.45 μm ﬁltration membrane
before analysis. Samples were extracted as follows: One hundred
ﬁfty milligrams of QSYQ was accurately weighed and
ultrasonically extracted with 10 ml of 50% (v/v) methanol by
ultrasonication for 30 min. After replenishing the lost weight
during extraction, samples were ﬁltered using a 0.45 μm ﬁltration
membrane for HPLC analysis.
The HPLC analysis of QSYQ was performed using an Agilent
1,290 Inﬁnity LC, which was equipped with a photodiode array
ultraviolet-visible detector. A Waters ACQUITY UPLC BEH
Shield RP18 column (2.1 × 100 mm, 1.7 µm) was used to
perform the chromatography separation using water (A) and
acetonitrile (B) as mobile phases. The gradient elution was set as
follows: 0–3 min, 15% B; 3–10 min, 15–20% B; 10–12 min, 20% B;
12–18 min, 20–40% B; 18–24 min, 40–70% B; 24–27 min,
70–95% B; and 27–28 min, 95–8% B. The column temperature
was maintained at 25°C with an injection volume of 2 μL and a
ﬂow rate of 0.4 ml/min for analysis. Dual-wavelength detection
was applied in this analysis: channel A was set as 254 nm; channel
B was set as 280 nm from 0 to 3 min and 325 nm from to 28 min.

Animal Grouping and Drug Treatment
After 22.5 h reperfusion, two independent observers, who were
blinded to the experiment, tested the neurological deﬁcits of the
animals that had undergone MCAO surgery according to a ﬁvepoint scale described previously by Longa et al. with a minor
modiﬁcation (Longa et al., 1989). The criteria were set as follows:
score 0, no neurological deﬁcit; score 1, mild focal neurological
deﬁcit (failure to fully extend contralateral forelimb); score 2,
moderate focal neurological deﬁcit (repetitive circling to the
contralateral side); score 3, severe focal neurological deﬁcit

Experimental Animals
Male Sprague-Dawley (SD) rats weighing 200–220 g were
obtained from Beijing Vital River Lab Animal Technology Co.,
Ltd. (Beijing, China, Certiﬁcate No: SCXK [Jing] 2014-0013). Rats
were housed under a 12 h light/dark cycle in polypropylene cages,
which were well ventilated, and there was a controlled in-house
temperature of 22 ± 2°C as well as humidity of 40 ± 5%.
Commercial rodent chow (Beijing Vital River Lab Animal
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with the ﬂoor during a step cycle), were employed for assessing the
effects of QSYQ on functional recovery. At least two observers who
were blinded to the animal grouping carried out the CatWalk test
and data analysis.

(falling to the contralateral side); and score 4, unable to walk
spontaneously with a depressed level of consciousness or death. A
total of 130 rats with a score between 1 and 2 were selected for the
present study. As shown in Supplementary Figure S1, apart from
the Sham group, the selected experimental rats were randomly
divided into ﬁve different groups, including I/R (model), Nim
(positive control)+I/R, QSYQ low dose (150 mg/kg) + I/R, middle
dose (300 mg/kg) + I/R, and high dose (600 mg/kg) + I/R groups.
Rats in QSYQ (150 mg/kg, 300 mg/kg, 600 mg/kg) and Nim
(12 mg/kg) groups were orally administered their respective
dose once daily for 7 days. Meanwhile, the Sham-operated and
I/R model groups were given 0.9% normal saline via gavage at a
dose of 10 ml/kg.

Micro-CT Imaging and Analysis
After 8 days post-reperfusion, anesthetized rats were intraarterially injected with a clinically available iodinated x-ray
contrast agent (Omnipaque) at 2.0 ml over a period of 20 s.
Subsequently, the micro-Computed Tomography (CT) imaging
technique was used to visualize the blood-brain barrier (BBB)
disruption and cerebral edema (Park et al., 2014; Orgah et al.,
2018). In brief, brain micro-CT imaging was performed using a
small animal micro-CT imager (Quantum FX; PerkinElmer,
United States) with the following main imaging parameters:
voltage for 90 kV, current for 180 μA, ﬁeld of view (FOV) for
40 mm, and scan for 4.5 min. BBB disruption was detected for
Omnipaque leakage and cerebral edema was presented with
position offset of midline. Next, the “VOL EDIT” module in
Analyze 12.0 image analysis software (Analyze Direct, Overland
Park, KS, United States) was applied to make 3D reconstructions
of whole-cerebral slide images. The “ROI” measure module was
used to calculate the mean micro-CT number (HU) of
Omnipaque leakage and cerebral hemisphere volumes.

Neurological Deﬁcits and Mortality Rate
For the evaluation of neurological function, a modiﬁed
Neurological Severity Score (mNSS) was used on days 1, 3, 5,
and 7, respectively after MCAO. The mNSS was a synthetic scale,
including motor function, sensory disturbance, balance, and
reﬂection tests, graded on a score of 0–18 (Chen et al., 2001).
The details were shown in Supplementary Table S1. One point was
deﬁned as inability to complete the tasks or no response to tests,
while higher scores represented more serious neurological deﬁcit.
All tests were assessed by two independent investigators who were
blinded to the experimental groups. The mortality rate of each
group was calculated for the whole period of the drug treatment.

TTC Staining and Quantiﬁcation of Infarct
Volume

Behavioral Assay
Open ﬁeld test was executed to evaluate the locomotor activity of
experimental animals (Jin et al., 2015). On the 8th day after stroke,
the rats were respectively placed in four open ﬁeld locomotion
chambers (50 cm in length× 50 cm in width× 40 cm wall height)
made of plywood. The bottom of the chamber was actually divided
by white drawn lines, composing nine equal-area grids. After 5 min
adaption to the novel environment, the locomotor data of each rat
was automatically recorded for 30 min and calculated using the
ANY-maze software (version 4.82, Stoelting, United States). The
following parameters were analyzed: total distance traveled by the
animals and average speed. The behavioral assessment was
performed in a quiet room, from 8:00–12:00 a.m., by two
observers who were blinded to the animal experiment.

After performing micro-CT imaging, brains were quickly
removed. Six pieces of 2 mm-thick coronal cerebral slices were
obtained using a rat brain matrix (Shenzhen RWD life technology
Co., Ltd., Guangzhou, China) and stained with 2% TTC solution
in the dark for 10 min at 37°C. After stained cerebral slices were
photographed, ImageJ image processing software (ImageJ 1.51,
Wayne Rasband, National Institutes of Health, United States) was
applied to measure cerebral infarct area. Ratios of infarct volume
were displayed as a percentage (%) of (total cerebral infarct
volume/total brain volume) ×100 (Lin et al., 1993).

Assessment of BBB Permeability
BBB permeability was examined by the extravasation of Evans
Blue (EB) stain into the brain following the tail-vein injection.
After 7 days post-reperfusion, rats were injected with 4% EB
solution in 0.9% normal saline (2 ml/kg) via the tail vein. 24 h
later, the brains suffering perfusion were cut into 2 mm-thick
coronal slices. After recording the EB-stained cerebral sections,
the Caliper IVIS Lumina K Series III system was used for
ﬂuorescent imaging detection [58]. Then, the Living Image
Software (version 4.3.1) was used to quantify the EB leakage
via calculating a total radiant efﬁciency [(p/s)/(μW/cm2)].

Gait Analysis
For the gait test, CatWalk XT 9.1 (Noldus Information Technology,
Wageningen, Netherlands), an automated quantitative gait analysis
system, was performed in this study (Orgah et al., 2019). Prior to
surgery, rats were trained for at least three consecutive days to
adapt to the walkway in a quiet room. On the 8th day after the
MCAO or sham-operation, post-surgery testing was executed in
the same conditions as the training period. Each experimental
animal was placed individually on the runway and allowed to freely
run back and forth until three accepted runs were recorded. The
subsequent data analysis was handled using the Catwalk XT 9.1
Software. The main gait parameters, including walking speed (the
speed of rats across the runway), base of support (distance between
girdle paw pairs), stride length (distance the paw traveled from one
step to the next), and stand (time duration of the paw in contact
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TMT-Based Quantitative Proteomics
Analysis

Sample Preparation
According to the above experimental results, rats from the model
group (n  3) and QSYQ high dose group (n  3) were screened to
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further perform proteomic analysis. A total of eight days after
MCAO, anesthetized rats were transcardially perfused with
prechilled saline and then the brains were immediately
removed. The infarcted cerebral hemisphere tissues were
separated, snap frozen in liquid nitrogen, and stored at -80°C
until use. Protein extraction from the cerebral tissues were carried
out referring to a method previously described (Zhu et al., 2014)
with some modiﬁcations. In brief, all samples were homogenized
in ice-cold lysis buffer. Subsequently, the homogenate was
sonicated and boiled for 15 min. After centrifugation at
14,000 g for 40 min at 4°C, the supernatant was ﬁltered with
0.22 µm ﬁlters. Protein content was determined using the BCA
protein assay kit.

Fisher Scientiﬁc). The labeled peptides were loaded onto a reverse
phase trap column (Thermo Scientiﬁc Acclaim PepMap100,
100 μm inner diameter× 2 cm, nanoViper C18) connected to
the C18-reversed phase analytical column (Thermo Scientiﬁc
Easy Column, 10 cm long, 75 μm inner diameter, 3 μm resin)
in buffer A (0.1% formic acid) and eluted with a 60 min linear
gradient - 0–50% buffer B (84% acetonitrile and 0.1% formic
acid), 50 min; 50–100% buffer B, 5 min; 100%–100% buffer B,
5 min - at a ﬂow rate of 300 nL/min controlled by IntelliFlow
technology. The mass spectrometer was operated in positive ion
mode. MS data was acquired using a data-dependent top 10
method dynamically choosing the most abundant precursor ions
from the survey scan (300–1800 m/z) for high-energy collision
dissociation (HCD) fragmentation. Automatic gain control
(AGC) target value was set to 3 × 106 with a maximum ion
injection time of 10 ms. Dynamic exclusion duration was 40.0 s.
The survey scans were acquired at a high resolution of 70,000
at m/z 200, resolution for HCD spectra was set to 17,500 at m/z
200, and isolation width was 2 m/z. Normalized collision energy
was 30 eV and the underﬁll ratio, which speciﬁed the minimum
percentage of the target value likely to be reached at maximum ﬁll
time, was deﬁned as 0.1%. The instrument was run with peptide
recognition mode enabled.

Protein Digestion Based on Filter-Aided
Sample Preparation
Protein digestion was performed according to the method of
ﬁlter-aided sample preparation (FASP) (Wisniewski et al., 2009).
200 μg of proteins for each sample were incorporated into 30 μL
SDT buffer (4% SDS, 100 mM DTT, 150 mM Tris-HCl pH 8.0).
The detergent, DTT, and other low-molecular-weight
components were removed using UA buffer (8 M Urea,
150 mM Tris-HCl pH 8.0) by repeated ultraﬁltration
(Microcon units, 10 kD). Then 100 μL iodoacetamide (100 mM
IAA in UA buffer) was added to block reduced cysteine residues
and the samples were incubated for 30 min in the dark. The ﬁlters
were washed with 100 μL UA buffer three times and then
100 μL100 mM TEAB buffer twice. Finally, the protein
suspensions were digested with 4 μg trypsin (Promega) in
40 μL TEAB buffer overnight at 37°C, and the resulting
peptides were collected as a ﬁltrate. The peptide content was
estimated by UV light spectral density at 280 nm using an
extinctions coefﬁcient of 1.1 of 0.1% (g/L) solution that was
calculated on the basis of the frequency of tryptophan and
tyrosine in vertebrate proteins.

Protein Identiﬁcation and Quantiﬁcation
The MS/MS spectra were searched using MASCOT engine
(Matrix Science, London, United Kingdom; version 2.2)
embedded into Proteome Discoverer 1.4 (Thermo Fisher
Scientiﬁc). Trypsin was chosen as the enzyme, allowing up to
two missed cleavage sites. Carbamidomethylation (C), TMT 6plex (N-term), and TMT 6-plex (lysine, K) were chosen as ﬁxed
modiﬁcation. Oxidation (methionine, M) was regarded as a
variable modiﬁcation. The peptide mass tolerances were set at
20 ppm for MS1 spectra acquired, and the fragment mass
tolerance for MS2 spectra was set to 0.1 Da. In this study, only
rank 1 peptide and a false discovery rate (FDR) of ≤1% were
accepted. The protein ratios were calculated as the median of only
unique peptides of the protein. All peptide ratios were normalized
by the median protein ratio, and the median protein ratio should
be 1 after the normalization. Comparisons of the protein
identiﬁcation and quantitation results were done between each
QSYQ high dose (H) and the corresponding model (M) groups.
Signiﬁcantly regulated proteins between experimental groups
were determined based on their p-value (p-value<0.05). Only
proteins with more than 1.20-fold or less than 0.833-fold change
compared to control groups were considered differentially
regulated.

TMT Labeling and Peptide Fractionation
According to the manufacturer’s instructions, 100 μg peptide
mixture of each sample was labeled using tandem mass tags
(TMT) isobaric label reagents (Thermo Fisher Scientiﬁc).
Subsequently, pierce high pH reversed-phase peptide
fractionation kit (Thermo Fisher Scientiﬁc, Waltham, MA,
United States) was used to fractionate TMT-labeled digest
samples into 15 fractions by an increasing acetonitrile stepgradient elution according to instructions (Wei et al., 2018).
The fractions were dried, lyophilized, and stored at -80 C until
LC-MS/MS analysis.

Bioinformatics Analysis
In this study, Cluster 3.0 (http://bonsai.hgc.jp/∼mdehoon/
software/cluster/software.htm) and Java Treeview software
(http://jtreeview.sourceforge.net) were used to perform
hierarchical clustering analysis. Euclidean distance algorithm
for similarity measure and average linkage clustering algorithm
(clustering uses the centroids of the observations) for clustering
were selected when carrying out hierarchical clustering. The
acquired protein relative expression data was visualized as a

Reversed-Phase Liquid
Chromatography-Tandem Mass
Spectrometry
The NanoLC-MS/MS analysis of each fraction was performed
using a Q Exactive mass spectrometer (Thermo Fisher Scientiﬁc)
that was coupled to an Easy nLC1000 HPLC system (Thermo
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tree heat map. Then, the data, including signiﬁcantly differential
protein name, p-value, and log(fold change), were imported into
Ingenuity Pathway Analysis (IPA) system (http://www.
ingenuity.com) to execute further analysis. “Core analysisDiseases and Functions” module was performed to obtain the
top diseases and functions related to the signiﬁcantly differential
proteins. “Build-Connection” module was used to analyze
protein-protein interaction (PPI) network.
According to the direct functional degree of each protein, the
importance of the protein in the PPI network was displayed.
“Path designer” module was used to polish the network images
and graphs.
The algorithm of the IPA analysis was based on Fisher’s exact
test with the enrichment score of p-value.

H&L (1:10,000) as the secondary antibody for 2 h at room
temperature. After incubation ﬁnished, the membrane was
washed three times (10 min each) and visualized using
enhanced chemiluminescence detection reagents (TransGen
Biotech Co., Ltd., Beijing, China). Western blotting bands
were captured using the C-DiGit scanner with Image Studio
(Version 5.2) imaging system. The quantiﬁcation of band
intensity was performed according to integrated density by
ImageJ image processing software (ImageJ 1.42, Wayne
Rasband, National Institutes of Health, United States).

®

Quantitative Real-Time Polymerase Chain
Reaction Analysis
Total RNA samples from the post-ischemic hemisphere tissues
were isolated using TRIzol reagent (Invitrogen, Thermo Fisher
Scientiﬁc, Inc., Waltham, MA, United States) according to the
manufacturer’s protocol. Subsequently, the complementary DNA
(cDNA) was synthesized from 1 µg total RNA in a 20 µL reaction
using Transcriptor First Strand cDNA Synthesis Kit (Roche,
Mannheim, Germany).
The Bestar Sybr Green qPCR Master Mix (DBI Bioscience,
Ludwigshafen, Germany) was used in reverse transcriptionquantitative real-time polymerase chain reaction (RT-qPCR) to
quantify the mRNA expression levels of LGALS3 (galectin-3),
TNF-α, and IL-6 with glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as an internal control. The designed
gene-speciﬁc primers were obtained by Sangon Biotech
(Shanghai, China) and the following oligonucleotide primer
sequences were used: for LGALS3 forward 5′-GAG AAC AAC
AGA AGA GTC ATC GTG-3′, reverse 5′-GAC CTG TAT TTT
GAA TGG TTT GCC-3′; for TNF-α forward 5′-GCG TGT TCA
TCC GTT CTC TA-3′, reverse 5′-CGT CTC GTG TGT TTC
TGA GC-3′; for IL-6 forward 5′-ACC TGG AGT TTG TGA AGA
ACA AC-3′, reverse 5′-GGA AGT TGG GGT AGG AAG GA-3′;
for GAPDH forward 5′-GGC CTT CCG TGT TCC TAC C-3′,
reverse 5′-CGC CTG CTT CAC CAC CTT C-3′.The
ampliﬁcation
and
analysis
were
performed
using
LightCycler 480 Software Version1.5.0.39 (Roche, Mannheim,
Germany) for 45 cycles. The relative mRNA expression levels
were calculated using 2−ΔΔCT method, following normalization
to the housekeeping gene GAPDH.

®

Immunohistochemistry Analysis
After 8 days post-reperfusion, brain tissues were quickly obtained
from euthanized rats and then ﬁxed in 4% paraformaldehyde for
at least 48 h. The ﬁxed tissues were dehydrated and embedded in
parafﬁn blocks to be cut into 5 μm cerebral coronal parafﬁn slices.
Subsequently, the sections were dewaxed in xylene and
rehydrated followed by incubation with 3% hydrogen peroxide
at room temperature for 10 min to block intrinsic peroxidase
activity. After performing antigen repair, the brain slices were
treated with blocking buffer (10% bovine serum) at 37 C for 1 h to
block any nonspeciﬁc antibody responses. Next step, the sections
were incubated overnight at 4 C using anti-galectin-3 antibody
diluted with blocking buffer (1:50), then sequentially incubated
with secondary antibody (the biotin-conjugated goat anti-rabbit
IgG) diluted with blocking buffer (1:200) for 40 min at 37 C. The
immunoreactivity of galectin-3 protein was visualized using a
DAB substrate kit, followed by counterstaining hematoxylin,
differentiation with 1% hydrochloric acid alcohol, dehydration,
and sealing. Finally, the optical microscope (Vectra 3,
PerkinElmer, United States) was carried out to observe and
photograph the brain slices. ImagePro Plus software (National
Institutes of Health, Bethesda, MD, United States) was executed
to quantify the expression of galectin-3 by calculating the average
optical density (AOD) value.

®

®

Western Blotting Analysis
The frozen post-ischemic hemisphere tissues (n  3 per group)
were collected in ice-cold RIPA lysis buffer containing serine
proteases and acetylcholinesterase inhibitors. The lysates were
centrifuged at 12,000 g for 10 min at 4 C. The BCA protein assay
kit was used to measure the protein concentration. Equal
amounts of 30 μg protein extracts were loaded and separated
by 12% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE)
and transferred to polyvinylidene ﬂuoride (PVDF) blotting
membrane (GE Healthcare, Millipore, United States) using an
electrophoresis apparatus (Tanon Science and Technology Co.,
Ltd., Shanghai, China). The membrane was blocked with a 5%
non-fat milk-Tris-HCl-buffered saline and Tween 20 (TBST)
solution for 3 h at room temperature, and then incubated
overnight at C with the antibodies of anti-Galectin-3 (1:1,000)
and anti-β-actin (1:2,000). After washing three times with
TBST, the membrane was incubated with goat anti-rabbit IgG
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Enzyme-Linked Immunosorbent Assay
After 8 days post-reperfusion, the blood samples were collected
from anesthetized rats. Then, blood samples were centrifuged at
10,000 rpm for 15 min at 4 C to separate and obtain the serum. In
order to measure the expression levels of TNF-α and IL-6 in
serum, the rat TNF-α ELISA kit (ZC-37624, ZCi Biotechnology
Co., Ltd.) and rat IL-6 ELISA kit (ZC-36404, ZCi Biotechnology
Co., Ltd.) were applied according to the manufacturer’s
instructions. Finally, the protein concentrations of TNF-α and
IL-6 in serum were calculated with the reference to the standard
curve acquired from a gradient concentration standard
substances provided by the assay kit.
Statistical analysis Statistical analysis was performed using
Student’s two-tailed t-test for comparison between two groups
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FIGURE 1 | Effect of treatment with QSYQ on survival rate and neurological as well as motor deﬁcits caused by stroke. (A) The Kaplan-Meier survival curve of each
group. Treatment with QSYQ at all doses or Nim improved the survival rate compared to the model group. (B) The mNSS scores on days 1, 3, 5, and 7 after I/R surgery.
The model group exhibited serious neurological deﬁcit among six groups on days 3, 5, and 7 after drug treatment, whereas QSYQ and positive control groups showed a
distinct reduction in mNSS scores. (C) Bar graph representing results of traveled total distance (n  15). QSYQ at middle and high doses/Nim + I/R groups obviously
improved the total traveled distance compared to the stroke rats. (D) Bar graph representing results of mean speed (n  15). QSYQ at middle and high doses/Nim + I/R
groups signiﬁcantly boosted the mean speed compared to the stroke rats. Data are expressed as the mean ± SD. #p< 0.05, ##p < 0.01, and ###p< 0.001 vs. the sham
group; *p< 0.05, **p< 0.01, and ***p< 0.001 vs. the model group. I/R, ischemia/reperfusion; Nim, Nimodipine; QSYQ-L, QSYQ 150°mg/kg-low dose; QSYQ-M, QSYQ
300°mg/kg-middle dose; QSYQ-H, QSYQ 600°mg/kg-high dose.

and using one-way analysis of variance (ANOVA) followed by
Dunnett’s t-test for comparisons between multiple groups. The
mortality was analyzed using the Kaplan-Meier survival curve. A
value of p< 0.05 was deﬁned as a statistically signiﬁcant
difference. Data from different experiments were expressed
either as mean ± SD or mean ± SEM as indicated. GraphPad
Prism 7 software (GraphPad Software, Inc., La Jolla, CA,
United States) was used to generate all data graphs.

rats treated with low and middle doses of QSYQ or Nim obviously
improved their survival rate (p＜0.05). Furthermore, treatment
with QSYQ at high doses (600 mg/kg) increased the survival rate
from 50 to 84% (p＜0.01; Figure 1A). As shown in Figure 1B,
rats subjected to sham operation behaved normally without
neurological deﬁcit symptoms, however, the left side cerebral
I/R surgery caused serious neurological deﬁcit of rats in the model
group. Compared with the model group, treatment with Nim or
different doses of QSYQ markedly decreased scores with better
neurological function. Moreover, QSYQ at middle and high doses
had similar effects on neurological function to the Nim group
(Figure 1B). In addition, we also carried out an open ﬁeld test to
measure the locomotor activity of experimental animals on poststroke day 8. The data of total distance traveled by the animals
and average speed within the 30 min indicated severe motor
deﬁcits in the model group (Figures 1C,D). Fortunately, the Nim,
QSYQ middle dose (300 mg/kg), and QSYQ high dose
(600 mg/kg) groups signiﬁcantly enhanced the locomotor
activity of stroke rats (p＜0.01).

RESULTS
Chemical Proﬁle of Major Ingredients in
QSYQ by HPLC
To elucidate the main chemical components in QSYQ, HPLC
analysis was performed in this study. A representative HPLC
chromatogram was displayed in Supplementary Figure S2.
Thirteen constituents in QSYQ were successfully identiﬁed
according to the comparison of the retention times with
standard substances, which was similar with the previous
report (Zhang et al., 2018).

QSYQ Ameliorated Motion Deﬁcits of
Subacute Stroke Rats

QSYQ Improved the Survival Rate and
Neurological Scores of Subacute Stroke
Rats

In this study, we applied CatWalk XT 9.1 system to conduct the
gait test of rats in each group 8 days after the MCAO or shamoperation. The collected footprints of rats from each group were
automatically labeled by the system as right front paw (RF), right
hind paw (RH), left front paw (LF), and left hind paw (LH). Once
auto-classiﬁcation of labeled footprints was ﬁnished, we could
obtain the corresponding gait parameters of each labeled paw.
Then, a one-way between subjects ANOVA was used to compare

The Kaplan-Meier survival curve showed the survival proportion
of the stroke-induced rats (Figure 1A). Rats after MCAO
signiﬁcantly increased mortality, especially during the acute
period of reperfusion (ﬁrst 72 h), compared to the sham group
within the 7 day period of data collection. As expected, MCAO
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FIGURE 2 | Locomotive gait analysis and functional recovery of QSYQ treated subacute stroke rats. (A–D) Bar graph representation of main parameter statistics,
including walking speed, BOS, stride length, and stand time, for estimating functional recovery of QSYQ-treated stroke rats (n  8). Left brain lesion induced by I/R
resulted in a signiﬁcant motion deﬁcits of rats. Fortunately, QSYQ treatment could attenuate the abnormal motion function during the 8th-days post-reperfusion. Data are
presented as the mean ± SD. #p< 0.05, ##p< 0.01, and ###p< 0.001 vs. the sham group; *p< 0.05, **p< 0.01, and ***p< 0.001 vs. the model group. I/R, ischemia/
reperfusion; Nim, Nimodipine; QSYQ-L, QSYQ 150°mg/kg-low dose; QSYQ-M, QSYQ 300°mg/kg-middle dose; QSYQ-H, QSYQ 600°mg/kg-high dose.

the effect of drugs on the function recovery of post-stroke motion
impairment for walking speed, base of support (BOS), stride
length, and stand time. In subacute phase of stroke, the rats
subjected to MCAO signiﬁcantly reduced walking speed, BOS,
and stride length as well as increased stand time (Figure 2).
Surprisingly, treatment with QSYQ could dose-dependently
enhance walking speed (Figure 2A). Secondly, MCAO rats
treated with QSYQ at high dose (600 mg/kg) obviously
increased BOS of their front paws and hind paws (Figure 2B).
For the parameter of stride length, treatment with QSYQ at
high dose (600 mg/kg) remarkably improved the impairment of
RH, LF, and LH caused by stroke, while treatment with QSYQ at
middle dose (300 mg/kg) only increased stride length in RH and
LF (Figure 2C). Treatment with high doses of QSYQ positively
reduced stand time of RF, RH, and LH (Figure 2D). As expected,
treatment with Nim also obviously improved the deﬁcit of
locomotor function induced by cerebral ischemia and
reperfusion (Figure 2).

(600 mg/kg) could exhibit a positive effect on reducing infarct
volume induced by I/R injury (Figures 3A,B). According to the
cerebral coronal image, we found that the model group presented
the most obvious midline offset caused by cerebral edema,
however, treatment with QSYQ at all three doses as well as
Nim lessened the degree of midline offset (Figure 3C).
Subsequently, Analyze 12.0 image analysis software was used
to calculate the cerebral edema. Compared with the sham group,
the ratio of the bilateral cerebral hemisphere volume markedly
elevated on account of undergoing left MCAO surgical operation
(Figure 3D). Similar to the result of Nim, treatment with QSYQ
at three doses inhibited the ratio of the bilateral cerebral
hemisphere volume, which conﬁrmed that QSYQ treatment
reduced cerebral edema in the subacute phase of the
experimental animal model of ischemic stroke (Figure 3D).

QSYQ Attenuated BBB Disruption in
Subacute Stroke Rats
IVIS ﬂuorescent imaging and brain micro-CT imaging techniques
were integrated to detect and quantify the BBB integrity. As a control,
no EB extravasation, Omnipaque leakage, and detectable spectrum
were observed in the sham group, whereas a signiﬁcant leakage (EB
and Omnipaque) of the BBB was detected in the model samples
(Figure 4). Notably, treatment with both Nim and QSYQ high dose
(600 mg/kg) signiﬁcantly lowered EB extravasation and Omnipaque
leakage (Figure 4). Treatment with QSYQ at middle dose
(300 mg/kg) also reduced Omnipaque leakage, whereas treatment
with QSYQ at middle dose (300 mg/kg) attenuated EB leakage to
some extent, but did not reach signiﬁcance (Figures 4D,E). The
results of EB and Omnipaque extravasation indicated that treatment

QSYQ Reduced Cerebral Infarction Volume
and Cerebral Edema in Subacute Stroke Rat
Brain
By calculating the cerebral infarction volume in TTC-stained
slices and indirectly assessing the severity of brain edema in
micro-CT imaging, the brain injury in different groups on the 8th
day after MCAO surgery was evaluated. Compared with the
sham-operated group, the infarct volume was signiﬁcantly
increased in the experimental ischemic stroke model group
(25.87 ± 2.88% of the cerebral volume), whereas treatment
with Nim, QSYQ middle dose (300 mg/kg), and high dose
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FIGURE 3 | Effect of treatment with QSYQ on cerebral infarction and cerebral edema in subacute stroke rat brain. (A) Representative images of TTC-stained brain
slices of each group. The infarct areas were in white, whereas normal areas were in red. (B) Quantitative analysis of cerebral infarction volumes of each group (n  6).
QSYQ/Nim + I/R group signiﬁcantly decreased the infarct volumes caused by MCAO. (C) Representative coronal cerebral slice image of each group. Yellow dotted line
marks the cerebral midline and red arrows indicate offset distance of midline. (D) Quantitative analysis of the ratio of bilateral brain hemisphere volume of each group
(n  6). Treatment with QSYQ at three doses as well as Nim decreased the raised values of the ratio of bilateral brain hemisphere volume due to left cerebral I/R injury. TTC
staining and cerebral edema data are presented as the mean ± SD. #p< 0.05, ##p< 0.01, and ###p< 0.001 vs. the sham group; *p< 0.05, **p< 0.01, and ***p<0.001 vs. the
model group. I/R, ischemia/reperfusion; Nim, Nimodipine; QSYQ-L, QSYQ 150°mg/kg-low dose; QSYQ-M, QSYQ 300°mg/kg-middle dose; QSYQ-H, QSYQ
600°mg/kg-high dose.

visualized in a tree heat map (Figure 5B), which supported the
rationality of selecting differentially expressed proteins. The
detailed information of signiﬁcantly differentially expressed
proteins was shown in Supplementary Table S2.

with QSYQ at high dose (600 mg/kg) or Nim observably reduced
BBB disruption of model rats in the subacute phase of experimental
stroke.

Identiﬁcation of Differentially Expressed
Proteins Induced by QSYQ Treatment in the
Brain of Subacute Stroke Rats.

Network Pharmacology Analysis Revealed
Galectin-3 Mediated Neuroinﬂammation as
a Sey Mechanism of Subacute Stroke
Protection by QSYQ.

To reveal the underlying molecular mechanisms of subacute
phase (1.5 h ischemia and 8 days reperfusion) stroke
protection against cerebral injury by QSYQ, TMT-based
quantitative proteomics analysis was employed on the proteins
extracted from ischemic brain tissues of MCAO/reperfusion rats
with or without QSYQ treatment. A total of 34,187 unique
peptides were detected (only rank 1 peptides and FDR ≤1%
were accepted) and 5,813 proteins were identiﬁed by one or
more unique peptides. Using a strict criteria (fold change >1.20 or
<0.833, p-value <0.05), a total of 92 differentially expressed
proteins in ischemic brain tissues were detected between
QSYQ (high dose)-treated and the model groups. Among
them, the expression levels of 40 proteins were signiﬁcantly
elevated with a fold change more than 1.20 in H (QSYQ high
dose group) vs. M (model group), whereas the expression levels of
52 proteins were dramatically reduced with a fold change less
than 0.833 in H (QSYQ high dose group) vs. M (model group), as
displayed in a volcano plot in Figure 5A. Hierarchical clustering
analysis of the acquired protein relative expression data were
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To discover the molecular mechanisms accounting for the action
of QSYQ treatment against ischemia and reperfusion injury,
network pharmacology analysis was carried out using IPA
system. The “Core analysis-Diseases and Functions” module
was executed to gain the top diseases and functions strongly
linked to the signiﬁcantly differentially expressed proteins. Based
on the Fisher’s exact test algorithm of IPA, the diseases as well as
functions were ranked according to corresponding p-value scores
so as to distinguish the relatedness or importance among these
proteins and diverse diseases as well as functions. The top 10
diseases and functions inﬂuenced by QSYQ in the order of
descending -log (p-value) score were inﬂammatory response,
cardiovascular disease, organismal injury and abnormalities,
neurological disease, renal and urological disease, cancer,
connective tissue disorders, inﬂammatory disease, skeletal and
muscular disorders, and developmental disorder. As the
inﬂammatory response ranked the highest with a -log
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FIGURE 4 | Treatment with QSYQ reduced the BBB breakdown in subacute stroke rats. (A) Representative images of cerebral coronal slices of the experimental
rats stained with EB dye after undergoing ischemic stroke (n  5–6). (B) The corresponding ﬂuorescent pictures of EB leakage of brain coronal sections (n  5–6). (C)
Representative cerebral micro-CT images of Omnipaque extravasation of each group (n  6). Red arrows indicate the position of Omnipaque extravasation. (D)
Quantitative analysis of EB leakage of cerebral coronal sections of rats in each group. Treatment with QSYQ at high dose/Nim markedly reduce EB leakage caused
by BBB disruption compared with the model group. (E) Quantitative analysis of brain Omnipaque leakage of rats from each group. Treatment with QSYQ at middle and
high doses as well as Nim signiﬁcantly lowered Omnipaque extravasation caused by BBB disruption. The data of total radiant efﬁciency are expressed as mean ± SEM.
The data of Omnipaque leakage are presented as mean SD. #p< 0.05, ##p < 0.01, and ###p < 0.001 vs. the sham group; *p< 0.05, **p< 0.01, and ***p< 0.001 vs. the
model group. I/R, ischemia/reperfusion; Nim, Nimodipine; QSYQ-L, QSYQ 150°mg/kg-low dose; QSYQ-M, QSYQ 300°mg/kg-middle dose; QSYQ-H, QSYQ
600°mg/kg-high dose.

FIGURE 5 | Identiﬁcation of differentially expressed proteins between QSYQ-treated group and the model group in ischemic brain of subacute stroke rats. (A)
Volcano plot of differentially expressed proteins regulated by QSYQ treatment. The differentially expressed proteins in tested samples were presented in different colors.
Red stands for the proteins of increased expression, green stands for the proteins of decreased expression, and black stands for proteins that are not differently
expressed. (B) A tree heat map of hierarchical clustering analysis of the individual brain samples (n  3). X-coordinates represented samples and Y-coordinates
represented the gene name of differentially expressed proteins. The log2 (fold change) value of differentially expressed proteins in tested samples was expressed in
different colors in the heat map, with red indicating up-regulation and blue indicating down-regulation. H means QSYQ at high dose (600 mg/kg) group; M means
model group.
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FIGURE 6 | (A) Diseases and Functions affected by QSYQ were ranked according to the Fisher’s exact test algorithm. Top 20 diseases and functions were
displayed in descending order based on -log (p-value) score. Among them, inﬂammatory response ranked the highest with a -log (p-value) score. (B) 30 important
proteins correlated with inﬂammatory response picked out from 92 differentially expressed proteins modulated by QSYQ. (C) PPI network of the differentially expressed
proteins. From the network, galectin-3 (LGALS3) and albumin (ALB) directly interact with the greatest number of proteins.

(p-value) score (Figure 6A), the result indicated that the antiinﬂammatory mechanism could be one of the most vital
mechanisms to explain QSYQ effective action against
experimental stroke. The corresponding differentially expressed
proteins involved in inﬂammatory response determined by “BuildGrow-Diseases and Functions” module of IPA (Figure 6B) showed
that 30 proteins, including galectin-3 (LGALS3), albumin (ALB),
cathepsin A (CTSA), clusterin (CLU), and transferrin (TF),
participated in the inﬂammatory response. PPI network analysis
positioned galectin-3 (LGALS3) and albumin (ALB) as the core
proteins regulated by QSYQ since they displayed the most
interactions with other signiﬁcantly differentially expressed
proteins revealed by our differential proteomic analysis
(Figure 6C). The detailed information of PPI network analysis
was shown in Supplementary Table S3.

7A–D, the protein expression level of galectin-3 was signiﬁcantly
increased in brain tissues of stroke rats in the subacute phase
compared with the sham group. Treatment with high dose
(600 mg/kg) of QSYQ markedly decreased galectin-3 expression
compared to rats that underwent MCAO and reperfusion (Figures
7A–D). This was consistent with the above quantitative proteomic
datasets. Since published literature reported that galectin-3
activated TLR-4 and downstream inﬂammatory targets like
nuclear factor κB (NF-κB), resulting in an increase in the release
of pro-inﬂammatory cytokines following brain injury (Burguillos
et al., 2015), we compared the mRNA expression of the following
genes - LGALS3 (galectin-3), TNF-α, and IL-6 - in rat brain samples
from the sham group, cerebral I/R injury model group, and model
treated with QSYQ (600 mg/kg) group by RT-qPCR. Compared
with the sham group, MCAO and reperfusion caused obvious
inﬂammation, as indicated by signiﬁcant upregulation of these
mRNA levels (Figures 7E–G). Importantly, treatment with high
dose (600 mg/kg) of QSYQ distinctly downregulated mRNA
expression of these neuroinﬂammation-related genes compared
to the model group (Figures 7E–G).

QSYQ Reversed Galectin-3 Mediated
Neuroinﬂammation in Subacute Stroke
Brain Tissues
Based on the results of network pharmacology analysis, the
differentially expressed protein of galectin-3 was found to act as
a critical target involved in QSYQ-regulated inﬂammatory response
during subacute stroke recovery. Both immunohistochemistry and
western blotting were performed to conﬁrm the results from the
TMT-based quantitative proteomics analysis. As shown in Figures
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QSYQ Reduced Proinﬂammatory Factors
TNF-α and IL-6 in Serum
To gain an insight into the regulatory role of QSYQ on galectin-3
mediated inﬂammation in subacute ischemic stroke, serum levels
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FIGURE 7 | The regulatory role of QSYQ on galectin-3 mediated neuroinﬂammation in response to cerebral ischemia and reperfusion injury. (A) Representative
images of immunohistochemical staining of galectin-3 protein expression in brain tissue slices (×200 magniﬁcation). (B) Quantiﬁcation of immunohistochemical staining (n
 3). (C) Representative images of western blotting of galectin-3. (D) The quantitative analysis of western blotting (n  3). Treatment with high doses of QSYQ signiﬁcantly
reduced the protein expression level of galectin-3 compared with the model group. Relative expression levels of cerebral LGALS3 (E), TNF-α (F), and IL-6 (G)
mRNA were evaluated by RT-qPCR (n  3). Results were normalized to GAPDH expression. Treatment with high dose of QSYQ signiﬁcantly decreased the mRNA
expression of galectin-3-mediated inﬂammation related genes. Quantitative assessment the effect of QSYQ treatment on the release of TNF-α (H) and IL-6 (I) in rats
serum following MCAO and reperfusion using ELISA kits (n  6). The data of western blotting and ELISA are expressed as mean ± SD. Meanwhile, the data of RT-qPCR
are presented as mean #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. the sham group; *p< 0.05, **p< 0.01, and ***p< 0.001 vs. the model group. I/R, ischemia/reperfusion;
QSYQ-H, QSYQ 600°mg/kg-high dose.

of TNF-α and IL-6 in different groups were determined by ELISA.
As shown in Figures 7H,I, concentrations of TNF-α and IL-6 in
serum were signiﬁcantly higher in rats that underwent MCAO/
reperfusion compared with that from sham-operated rats. As
expected, treatment with QSYQ at high dose (600 mg/kg)
markedly lowered the serum concentrations of TNF-α and IL6 compared with the model group (Figures 7H,I).

However, questions remain on whether QSYQ contributes to
the therapeutic post-stroke recovery and, if so, what the
underlying mechanisms are.
To evaluate the efﬁcacy of QSYQ for post-stroke recovery, we
chose Nim as a positive control drug in the present study. Nim is a
dihydropyridine calcium channel blocker and has been observed
for its therapeutic application in stroke. Babu et al. showed that
administration of Nim alleviated excitotoxicity and neurological
deﬁcits in experimental ischemic stroke rats (Babu and
Ramanathan, 2011). Liu et al. found that Nim treatment
reduced infarct volume and pathological damage and
improved neurological function of subacute stroke animals
(Liu et al., 2016). The beneﬁcial effect of Nim on protecting
BBB integrity has also been reported (Li et al., 2019). Since
neurological and motor deﬁcits are common in stroke
patients, improvement of neural and behavioral outcomes are
considered as necessary to estimate the action of anti-stroke drugs
(Benjamin et al., 2019). Therefore, in addition to the parameters
used in our previous acute CI/RI study, mNSS, open ﬁeld test, and
gait test were integrated to systematically evaluate the
neuroprotective function of QSYQ on promoting post-stroke
recovery in this work. Similar to Nim, the results indicated
that treatment with QSYQ at middle (300 mg/kg) and high
dose (600 mg/kg) markedly inhibited cerebral infarct volume
as well as ameliorated neurological and behavioral impairment
in subacute stroke rats (Figures 1–3), which revealed the
beneﬁcial effect of QSYQ on functional recovery.

DISCUSSION
Recovery after stroke is a complex, dynamic, multifactorial, and
multicellular process (Alawieh et al., 2018; Sadler et al., 2020).
No drugs or therapies have been approved for stroke recovery to
date, in part due to inappropriate experimental models and
because screen strategies focusing on single targets and drug
molecules were used (Cramer, 2015). Our current study tested a
hypothesis that a multi-component medicine, such as QSYQ,
targeting different biological pathways would be more effective
for post-stroke recovery. At present, QSYQ with the function of
Qi-tonifying and blood-activating has been widely used to treat
cardiovascular disease in clinic (Han et al., 2019). In addition to
the cardioprotection against ischemia/reperfusion injury, we
recently also reported the protective effect of pretreatment with
QSYQ against CI/RI, which may be partly related to the
modulation of neuroinﬂammatory response in an acute
stroke model (Chen et al., 2015; Wang et al., 2020).
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BBB dysfunction, characterized by the structural disruption of
tight junction protein complexes causing increased permeability,
ion transporter dysfunction leading to cerebral edema, and further
inﬂammatory damage induced by the inﬁltration and
accumulation of peripheral immune cells and the activation of
resident microglial cells, is a prominent pathological feature of
ischemic stroke (Jiang et al., 2018). Damage to BBB permeability
after cerebral ischemia and reperfusion is apparent in both the
acute and subacute phases of ischemic stroke (∼1–7°days) (Jiang
et al., 2012). In response to CI/RI, multiple mechanisms may be
involved in the restoration of BBB integrity, such as inﬂammatory
response, oxidative stress, and angiogenesis (Jiang et al., 2018). The
therapeutic strategies to promote BBB repair may enhance the
functional recovery of the subject after ischemic stroke (Boese et al.,
2018). In this study, the IVIS ﬂuorescent imaging and brain microCT imaging techniques were respectively applied to measure BBB
permeability. Signiﬁcantly, treatment with QSYQ at high dose
(600 mg/kg) and Nim obviously reduced the extravasation of EB
and Omnipaque on account of BBB breakdown after ischemic
stroke, which suggested the positive action of QSYQ against BBB
disruption caused by ischemia and reperfusion (Figure 4). The data
of micro-CT imaging also indicated decreased cerebral edema after
three doses of QSYQ treatment, which could be observed in the
subacute stage of CI/RI (Figures 3C,D).
Proteomics analysis takes a holistic approach to deciphering
the complexity of biological systems and to characterizing protein
interactions and biological networks that mediate physiological
and pathological processes of diseases (Ji et al., 2015). In recent
years, it has been increasingly applied to reveal the underlying
mechanisms of TCM for multiple therapeutic effects on stroke
treatment (Ning et al., 2012; Ji et al., 2015). TMT-based
proteomics technique, employing chemical peptide labeling
with amine-reactive isobaric tags, is a reliable method for
large-scale multiplexed proteins relative quantiﬁcation between
multiple samples within a single experiment (Rauniyar et al.,
2013). In this study, we applied TMT-based proteomics (TMTLC-MS/MS) to label ischemic rat brain tissue samples to identify
differentially expressed proteins following QSYQ treatment. As a
result, a total of 5,813 proteins were identiﬁed, of which 92 were
signiﬁcantly differentially expressed (fold change >1.20 or
<0.833, p-value <0.05) (Figure 5A). IPA analysis revealed that
among the differentially expressed proteins, those with the
highest -log (p-value) score were closely associated with
inﬂammatory
response,
suggesting
that
post-stroke
inﬂammation may be one of the main mechanisms underlying
the beneﬁcial action of QSYQ in enhancing functional recovery
after CI/RI (Figures 6A,B). Importantly, subsequent PPI network
analysis revealed that an inﬂammation-related protein named
galectin-3 (LGALS3) could be tightly networked with other
proteins (Figure 6C) and serve as a key player of QSYQ
action at the subacute phase of stroke.
Inﬂammation has been recognized as a double-edged sword
which could be either detrimental or beneﬁcial depending on the
particular stages after a stroke. In response to acute ischemic
stroke, resident glial cells activation, inﬁltration of peripheral
immune cells, release of pro-inﬂammatory cytokines and BBB
disruption together orchestrate the post-stroke augmented
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inﬂammatory response, which contribute to a series of longterm secondary brain damages and neurological behavioral
deﬁcits (Rajkovic et al., 2018; Wang et al., 2018). In the late
repair phase of CI/RI, neuroinﬂammation fundamentally
participates in multiple brain recovery processes, including
post-stroke neurogenesis, neurovascular unit remodeling, poststroke synaptogenesis, and axonal sprouting, which
synergistically promote neurological behavioral outcomes
(Wang et al., 2018). Currently, the regulation of inﬂammation
is considered as a primary target for the development of stroke
therapies.
Recently, growing evidence has suggested that galectin-3 could
act as an endogenous regulator of brain injury-related
inﬂammation (Shin, 2013; Rahimian et al., 2018). In response to
cerebral damage induced by stroke, high level expression of
galectin-3 was observed in activated microglial cells localized in
the ischemic lesion (Lalancette-Hebert et al., 2012). Burguillos et al.
showed that microglia-secreted galectin-3 acted as an endogenous
ligand for TLR-4 activation to amplify the pro-inﬂammatory
response and led to hippocampal degeneration in the injured
brain caused by ischemia (Burguillos et al., 2015). However,
galectin-3 deﬁciency reduced the expression of proinﬂammatory cytokines and exerted a neuroprotective effect
(Yip et al., 2017). Prins et al. reported that the absence of
galectin-3 attenuated neuroinﬂammation and ameliorated
neurological functional recovery after spinal cord injury (Prins
et al., 2016). These ﬁndings suggested that galectin-3 could be
regarded as a major immunomodulatory molecule that played a
signiﬁcant role in the modulation of brain inﬂammation and
neurodegeneration. In this study, we found that treatment with
QSYQ (600 mg/kg) distinctly downregulated the high expression
level of galectin-3 protein in brain tissues from MCAO/reperfusion
rats according to the quantitative proteomics analysis results,
which was veriﬁed with the methods of RT-qPCR,
immunohistochemistry, and western blot analysis (Figures
7A–E). The results indicated that the neuroprotective function
of QSYQ against the subacute phase of CI/RI might act partly
through the regulation of galectin-3-mediated inﬂammatory
response.
The inﬂammatory cytokines, tumor necrosis factor-alpha
(TNF-α) and interleukin-6 (IL-6), are generally considered to be
representative contributors to neuroinﬂammation in ischemic
stroke and are therefore promising potential targets in future
stroke therapy (Lambertsen et al., 2019). In experimental stroke
model of rodents, the increased expression levels of TNF-α mRNA
and protein were observed in ischemic brain tissues (Berti et al.,
2002; Haddad et al., 2006). In the subacute phase of CI/RI, the
upregulated level of TNF-α and IL-6 contents could be detected in
damaged brain tissues (Yang et al., 2019). The enhanced serum
levels of TNF and IL-6 in stroke patients were tested on days 1, 3,
and 7 after stroke when compared to the control group (Jiang et al.,
2017). Furthermore, TNF-α was also reported to regulate neuronal
networks involved in cognition and behavior (Baune et al., 2008).
In the present work, we further showed that treatment with QSYQ
(600 mg/kg) signiﬁcantly reduced the mRNA levels of TNF-α and
IL-6 in brain tissues of stroke rats after ischemia and reperfusion
(Figures 7F,G). Moreover, the serum levels of TNF-α and IL-6
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Laboratory Animal Ethics Committee of Tianjin University of
TCM (Permit number: TCM-LAEC2016036) as well as Tianjin
International Joint Academy of Biotechnology and Medicine
(Permit number: TJAB-TJU20160024).

were markedly increased in the subacute phase of stroke, which
were reversed by QSYQ (600 mg/kg) (Figures 7H,I). The data
suggested that the beneﬁcial effects of QSYQ on brain damage and
neurological behavioral dysfunction induced by experimental
stroke were partly via the modulation of galectin-3-mediated
inﬂammatory reaction.
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Although we demonstrated the efﬁcacy and mechanism of QSYQ
for post-stroke recovery, there are still limitations to this study.
First, the clinical relevance of the rat subacute stroke model we
used needs to be tested in human studies. Secondly, models of
longer-term recovery are to be established and optimized to
evaluate drugs and treatments that will beneﬁt real-time
patients. Thirdly, differential contributions of Yiqi (Qibeneﬁtting, i.e., Huangqi) and Huoxue (Blood-activiting,
i.e., Danshen + Sanqi) components of QSYQ need to be
distinguished and the active components involved needs deﬁning.

CONCLUSION
In summary, the current work provides the ﬁrst evidence for the
beneﬁcial action of treatment with QSYQ against the subacute
phase of CI/RI, which may be closely associated with its potential
to inhibit MCAO/reperfusion-induced upregulation of braininjury-related inﬂammatory regulator galectin-3, as well as the
pro-inﬂammatory cytokines TNF-α and IL-6. The results suggest
that QSYQ exerts a neuroprotective role in the damaged brain
caused by experimental stroke probably through modulating the
galectin-3-mediated inﬂammatory response. The fact that QSYQ
can improve post-stroke outcome needs further clariﬁcation, and
more thorough and reliable experimental data are required to
support its clinical application. Our study may provide a novel
therapeutic agent of ischemic stroke.
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